keyword
MENU ▼
Read by QxMD icon Read
search

Breast cancer luminal b

keyword
https://www.readbyqxmd.com/read/28723628/ese-1-elf3-mrna-expression-associates-with-poor-survival-outcomes-in-her2-breast-cancer-patients-and-is-critical-for-tumorigenesis-in-her2-breast-cancer-cells
#1
Adwitiya Kar, Arthur Gutierrez-Hartmann
ESE-1/Elf3 and HER2 appear to establish a positive feedback regulatory loop, but the precise role of ESE-1 in HER2+ breast tumorigenesis remains unknown. Analyzing public repositories, we found that luminal B and HER2 subtype patients with high ESE-1 mRNA levels displayed worse relapse free survival. We stably knocked down ESE-1 in HER2+ luminal B BT474 cells and HER2 subtype SKBR3 cells, which resulted in decreased cell proliferation, colony formation, and anchorage-independent growth in vitro. Stable ESE-1 knockdown inhibited HER2-dependent signaling in BT474 cells and inhibited mTOR activation in SKBR3 cells, but reduced Akt signaling in both cell types...
June 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/28713192/foxp3-allelic-variants-and-haplotype-structures-are-associated-with-aggressive-breast-cancer-subtypes
#2
Bruna Karina Banin Hirata, Roberta Losi Guembarovski, Glauco Akelinghton Freire Vitiello, Alda Losi Guembarovski, Karen Brajão de Oliveira, Maria Angelica Ehara Watanabe
FOXP3 genetic polymorphisms have been associated with cancer development and prognosis. In this context, the present study aimed to evaluate the g.10403A>G (rs2232365) polymorphisms and g.8048A>C (rs3761548), in aggressive breast cancer (BC) subtypes, including, Luminal B HER2+ (LB), HER2-enriched (HER2+), and triple-negative (TN). Polymerase chain reaction followed by enzymatic restriction was performed to genotyping 117 BC samples and 300 controls. A significant association of AA genotype (g.10403A>G) in relation to BC susceptibility (OR = 1...
2017: Disease Markers
https://www.readbyqxmd.com/read/28712009/analysis-of-molecular-subtypes-for-the-increased-her2-equivocal-cases-caused-by-application-of-the-updated-2013-asco-cap-her2-testing-guidelines-in-breast-cancer
#3
Lei Guo, Pei Yuan, Jing Zhang, Yun Ling, Wenbin Li, Bohui Zhao, Jianming Ying, Lixue Xuan
PURPOSE: Accurate testing of the status of human epidermal growth factor receptor type 2 (HER2) is a prerequisite for HER2-directed therapy. The American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) published joint guideline recommendations for HER2 testing in breast cancer in 2007 and it was updated in 2013. We compared the HER2 gene amplification status based on these two guidelines and analyzed the molecular characteristics of the equivocal cases...
July 15, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28711994/-18-f-fdg-pet-ct-features-for-the-molecular-characterization-of-primary-breast-tumors
#4
Lidija Antunovic, Francesca Gallivanone, Martina Sollini, Andrea Sagona, Alessandra Invento, Giulia Manfrinato, Margarita Kirienko, Corrado Tinterri, Arturo Chiti, Isabella Castiglioni
PURPOSE: The aim of this study was to evaluate the role of imaging features derived from [(18)F]FDG-PET/CT to provide in vivo characterization of breast cancer (BC). METHODS: Images from 43 patients with a first diagnosis of BC were reviewed. Images were acquired before any treatment. Histological data were derived from pretreatment biopsy or surgical histological specimen; these included tumor type, grade, ER and PgR receptor status, lymphovascular invasion, Ki67 index, HER2 status, and molecular subtype...
July 15, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28711937/magnetic-resonance-metabolic-profiling-of-estrogen-receptor-positive-breast-cancer-correlation-with-currently-used-molecular-markers
#5
Ji Soo Choi, Dahye Yoon, Ja Seung Koo, Siwon Kim, Vivian Youngjean Park, Eun-Kyung Kim, Suhkmann Kim, Min Jung Kim
Estrogen receptor (ER)-positive breast cancers overall have a good prognosis, however, some patients suffer relapses and do not respond to endocrine therapy. The purpose of this study was to determine whether there are any correlations between high-resolution magic angle spinning (HR-MAS) magnetic resonance spectroscopy (MRS) metabolic profiles of core needle biopsy (CNB) specimens and the molecular markers currently used in patients with ER-positive breast cancers. The metabolic profiling of CNB samples from 62 ER-positive cancers was performed by HR-MAS MRS...
June 28, 2017: Oncotarget
https://www.readbyqxmd.com/read/28711929/predictive-value-of-molecular-subtyping-in-nmibc-by-rt-qpcr-of-erbb2-esr1-pgr-and-mki67-from-formalin-fixed-tur-biopsies
#6
Johannes Breyer, Ralph Markus Wirtz, Wolfgang Otto, Mark Laible, Kornelia Schlombs, Philipp Erben, Maximilian Christian Kriegmair, Robert Stoehr, Sebastian Eidt, Stefan Denzinger, Maximilian Burger, Arndt Hartmann
Expression of ESR1, PGR, HER2 and Ki67 is important for risk stratification and therapy in breast cancer. Hormone receptor expression can also be found in MIBC, reflecting luminal and basal subtypes of breast cancer. Thus the purpose was to investigate on the mRNA expression of the aforementioned markers and their prognostic value in pT1 bladder cancer. Retrospective analysis of clinical data and Formalin-Fixed Paraffin-Embedded tissues (FFPE) of patients with stage pT1 NMIBC who underwent transurethral resection of the bladder was performed...
June 28, 2017: Oncotarget
https://www.readbyqxmd.com/read/28707744/the-impact-of-molecular-subtype-on-breast-cancer-recurrence-in-young-women-treated-with-contemporary-adjuvant-therapy
#7
Hanan Alabdulkareem, Tiffany Pinchinat, Sarah Khan, Alyssa Landers, Paul Christos, Rache Simmons, Tracy-Ann Moo
Breast cancer is the leading cause of cancer death in women younger than 40 years. Triple-negative breast cancer (TNBC) and human epidermal growth factor receptor-2 (HER2) positive subtypes have a particularly poor prognosis in this age group. The purpose of this study was to compare rates of recurrence among breast cancer subtypes in young patients treated with modern adjuvant systemic therapy. A retrospective review of breast cancer patients managed at a major academic breast center between May 2000 and November 2014 was performed...
July 14, 2017: Breast Journal
https://www.readbyqxmd.com/read/28704967/variability-in-dna-repair-capacity-levels-among-molecular-breast-cancer-subtypes-triple-negative-breast-cancer-shows-lowest-repair
#8
Jaime Matta, Carmen Ortiz, Jarline Encarnación, Julie Dutil, Erick Suárez
Breast cancer (BC) is a heterogeneous disease which many studies have classified in at least four molecular subtypes: Luminal A, Luminal B, HER2-Enriched, and Basal-like (including triple-negative breast cancer, TNBC). These subtypes provide information to stratify patients for better prognostic predictions and treatment selection. Individuals vary in their sensitivities to carcinogens due to differences in their DNA repair capacity (DRC) levels. Although our previous case-control study established low DRC (in terms of NER pathway) as a BC risk factor, we aim to study this effect among the molecular subtypes...
July 12, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28702505/human-snorna-93-is-processed-into-a-microrna-like-rna-that-promotes-breast-cancer-cell-invasion
#9
Dillon G Patterson, Justin T Roberts, Valeria M King, Dominika Houserova, Emmaline C Barnhill, Aline Crucello, Caroline J Polska, Lucas W Brantley, Garrett C Kaufman, Michael Nguyen, Megann W Santana, Ian A Schiller, Julius S Spicciani, Anastasia K Zapata, Molly M Miller, Timothy D Sherman, Ruixia Ma, Hongyou Zhao, Ritu Arora, Alexander B Coley, Melody M Zeidan, Ming Tan, Yaguang Xi, Glen M Borchert
Genetic searches for tumor suppressors have recently linked small nucleolar RNA misregulations with tumorigenesis. In addition to their classically defined functions, several small nucleolar RNAs are now known to be processed into short microRNA-like fragments called small nucleolar RNA-derived RNAs. To determine if any small nucleolar RNA-derived RNAs contribute to breast malignancy, we recently performed a RNA-seq-based comparison of the small nucleolar RNA-derived RNAs of two breast cancer cell lines (MCF-7 and MDA-MB-231) and identified small nucleolar RNA-derived RNAs derived from 13 small nucleolar RNAs overexpressed in MDA-MB-231s...
2017: NPJ Breast Cancer
https://www.readbyqxmd.com/read/28701032/bcl2-regulation-according-to-molecular-subtype-of-breast-cancer-by-analysis-of-the-cancer-genome-atlas-database
#10
Ki-Tae Hwang, Kwangsoo Kim, Ji Hyun Chang, Sohee Oh, Young A Kim, Jong Yoon Lee, Se Hee Jung, In Sil Choi
Purpose: We investigated BCL2 regulation across DNA, RNA, protein, and methylation status according to molecular subtype of breast cancer using The Cancer Genome Atlas (TCGA) database. Materials and Methods: We analyzed clinical and biological data on 1,096 breast cancers from the TCGA database. Biological data included reverse phase protein array (RPPA), mRNA sequencing (mRNA seq), mRNA microarray, methylation, copy number alteration linear, copy number alteration nonlinear, and mutation data...
July 4, 2017: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/28698184/the-association-of-mammographic-density-and-molecular-breast-cancer-subtype
#11
Brandy L Edwards, Kristen A Atkins, George J Stukenborg, Wendy M Novicoff, Krista N Larson, Wendy F Cohn, Jennifer A Harvey, Anneke T Schroen
BACKGROUND: Mammographic density (MD) is associated with increased breast cancer (BC) risk, yet limited data exists on an association between MD and BC molecular subtypes. METHODS: Women 18 years and older with BC and available mammograms between 2003-2012 were enrolled in a larger study on MD. MD was classified by Breast Imaging Reporting and Data System (BI-RADS) classification and by volumetric breast percent density (Volpara SolutionsTM). Subtype was assigned by hormone receptor-status, tumor grade and mitotic score (MS)...
July 11, 2017: Cancer Epidemiology, Biomarkers & Prevention
https://www.readbyqxmd.com/read/28693173/predictive-and-prognostic-significance-of-cd8-tumor-infiltrating-lymphocytes-in-patients-with-luminal-b-her-2-negative-breast-cancer-treated-with-neoadjuvant-chemotherapy
#12
Khalid Al-Saleh, Nashwa Abd El-Aziz, Arwa Ali, Waleed Abozeed, Ahmed Abd El-Warith, Ahmed Ibraheem, Jawaher Ansari, Ammar Al-Rikabi, Sufia Husain, Jean-Marc Nabholtz
The immunobiology of breast cancer (BC) subtypes, including luminal cancer, remains unclear. Cluster of differentiation (CD)8(+) tumor-infiltrating lymphocytes (TIL) are essential components of tumor-specific cellular adaptive immunity. However, only few studies have addressed the significance of cluster of differentiation 8(+)(CD8(+)) TIL in patients with luminal BC. The present study aimed to evaluate the predictive and prognostic significance of CD8(+) TIL in patients with luminal B/human epidermal growth factor receptor 2 (HER 2)-negative BC treated with anthracycline-based neoadjuvant chemotherapy (NC)...
July 2017: Oncology Letters
https://www.readbyqxmd.com/read/28690653/high-histologic-grade-and-high-ki-67-expression-predict-phenotypic-alterations-in-node-metastasis-in-primary-breast-cancers
#13
Pablo Mandó, Manglio Rizzo, Constanza Perez de la Puente, Mercedes Maino, Carolina Ponce, Maria Teresa Pombo, Mora Amat, Maria Victoria Costanzo, Adrian Nervo, Jorge Nadal, Veronica Fabiano, Jose Loza, Carlos Martin Loza, Federico Colo, Chacon Reinaldo
PURPOSE: Several studies have shown that estrogen receptor (ER) and progesterone receptor (PR) expression and human epidermal growth factor receptor 2 (HER2) expression may vary during tumoral progression. We aimed to describe and compare ER, PR, and HER2 expressions in primary breast tumors and synchronic axillary nodal metastases, and evaluate phenotypic correlations between them. METHODS: Patients were identified prospectively through surgical procedures between September 2013 and July 2016...
June 2017: Journal of Breast Cancer
https://www.readbyqxmd.com/read/28673861/cpsf6-is-a-clinically-relevant-breast-cancer-vulnerability-target-role-of-cpsf6-in-breast-cancer
#14
Najat Binothman, Ibrahim Y Hachim, Jean-Jacques Lebrun, Suhad Ali
Breast cancer represents a major health challenge. The majority of breast cancer deaths are due to cancer progression/recurrence for which no efficient therapies exist. Aggressive breast cancers are characterized by loss of cellular differentiation. Defining molecular mechanisms/targets contributing to cancer aggressiveness is needed to guide the design of new screening and targeted treatments. Here, we describe a novel tumor promoting function for the Cleavage and Polyadenylation Factor-6 (CPSF6). Importantly, aggressive breast cancer cells of luminal B, HER2-overexpressing and triple negative subtypes show dependency on CPSF6 for viability and tumorigenic capacity...
June 24, 2017: EBioMedicine
https://www.readbyqxmd.com/read/28673085/large-scale-analysis-of-breast-cancer-related-conformational-changes-in-proteins-using-silac-sprox
#15
Fang Liu, He Meng, Michael C Fitzgerald
Proteomic methods for disease state characterization and biomarker discovery have traditionally utilized quantitative mass spectrometry methods to identify proteins with altered expression levels in disease states. Here we report on the large-scale use of protein folding stability measurements to characterize different subtypes of breast cancer using the Stable Isotope Labeling with Amino Acids in Cell Culture and Stability of Proteins from Rates of Oxidation (SILAC-SPROX) technique. Protein folding stability differences were studied in a comparison of two luminal breast cancer subtypes, luminal-A and -B (i...
July 3, 2017: Journal of Proteome Research
https://www.readbyqxmd.com/read/28670879/molecular-subtypes-of-breast-cancers-from-myanmar-women-a-study-of-91-cases-at-two-pathology-centers
#16
Thar Htet San, Masayoshi Fujisawa, Soichiro Fushimi, Lamin Soe, Ngu Wah Min, Teizo Yoshimura, Toshiaki Ohara, Myint Myint Yee, Shinsuke Oda, Akihiro Matsukawa
Background: Breast cancer is the most common cancer in Myanmar women. Revealing the hormonal receptor status, human epidermal growth factor receptor 2 (HER2) and Ki-67 expression is useful for estimating patient prognosis as well as determination of treatment strategy. However, immunohistochemical features and classification of molecular subtypes in breast cancers from Myanmar remain unknown. Methods: The clinicopathological features of 91 breast cancers from Myanmar women were examined. Immunohistochemistry was performed on tissue specimens with antibodies to estrogen receptor (ER), progesterone receptor (PgR), HER2, Ki-67, cytokeratin (CK)5/6 and CK14...
June 25, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/28657689/neoadjuvant-chemotherapy-with-mri-monitoring-for-breast-cancer
#17
R V Dave, R Millican-Slater, D Dodwell, K Horgan, N Sharma
BACKGROUND: Neoadjuvant chemotherapy (NACT) is increasingly being offered to patients with breast cancer. No survival benefit has been demonstrated for NACT, but it may serve to reduce tumour size and improve prognosis through the attainment of a pathological complete response (pCR). The role and mode of MRI monitoring during NACT remain unclear. METHODS: Patients managed with NACT at a UK centre over 7 years were studied using a prospectively maintained database, which also included details of MRI...
June 28, 2017: British Journal of Surgery
https://www.readbyqxmd.com/read/28649649/patterns-of-cell-cycle-checkpoint-deregulation-associated-with-intrinsic-molecular-subtypes-of-human-breast-cancer-cells
#18
Jacquelyn J Bower, Leah D Vance, Matthew Psioda, Stephanie L Smith-Roe, Dennis A Simpson, Joseph G Ibrahim, Katherine A Hoadley, Charles M Perou, William K Kaufmann
Genomic instability is a hallmark of breast cancer, contributes to tumor heterogeneity, and influences chemotherapy resistance. Although Gap 2 and mitotic checkpoints are thought to prevent genomic instability, the role of these checkpoints in breast cancer is poorly understood. Here, we assess the Gap 2 and mitotic checkpoint functions of 24 breast cancer and immortalized mammary epithelial cell lines representing four of the six intrinsic molecular subtypes of breast cancer. We found that patterns of cell cycle checkpoint deregulation were associated with the intrinsic molecular subtype of breast cancer cell lines...
2017: NPJ Breast Cancer
https://www.readbyqxmd.com/read/28634940/3d-primary-culture-model-to-study-human-mammary-development
#19
Daniel H Miller, Ethan S Sokol, Piyush B Gupta
We present a protocol for expanding human mammary tissues from primary patient-derived cells in three-dimensional (3D) cultures. The primary epithelial cells are seeded into 3D hydrogels with defined components, which include both proteins and carbohydrates present in mammary tissue. Over a span of 10-14 days, the seeded cells form mammary tissues with complex ductal-lobular topologies and include luminal and basal cells in the correct orientation, together with cells that stain positively for stem cell markers...
2017: Methods in Molecular Biology
https://www.readbyqxmd.com/read/28624801/bromodomain-inhibition-shows-antitumoral-activity-in-mice-and-human-luminal-breast-cancer
#20
Montserrat Pérez-Salvia, Laia Simó-Riudalbas, Pere Llinàs-Arias, Laura Roa, Fernando Setien, Marta Soler, Manuel Castro de Moura, James E Bradner, Eva Gonzalez-Suarez, Catia Moutinho, Manel Esteller
BET bromodomain inhibitors, which have an antitumoral effect against various solid cancer tumor types, have not been studied in detail in luminal breast cancer, despite the prevalence of this subtype of mammary malignancy. Here we demonstrate that the BET bromodomain inhibitor JQ1 exerts growth-inhibitory activity in human luminal breast cancer cell lines associated with a depletion of the C-MYC oncogene, but does not alter the expression levels of the BRD4 bromodomain protein. Interestingly, expression microarray analyses indicate that, upon JQ1 administration, the antitumoral phenotype also involves downregulation of relevant breast cancer oncogenes such as the Breast Carcinoma-Amplified Sequence 1 (BCAS1) and the PDZ Domain-Containing 1 (PDZK1)...
May 29, 2017: Oncotarget
keyword
keyword
93454
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"